Table I.

Compound Table with Physicochemical Properties, BCS Class, In Vitro Dissolution, Dog and Clinical Food-Effect Ratio

Drug	Mol. type	BCS class	Log P	In vitro AUC FE ratio	Dog dose (mg)	Dog AUC FE ratio	Human dose (mg)	Human AUC FE ratio	Reference
BMS-A	Base	2	2.36	1.04	30	0.9	40	1.17	BMS
BMS-B	Base	4	3.87	3.29	–	–	300	3.17	BMS
BMS-C	Acid	2	5.09	2.05	100	2.1	200	2.1	BMS
BMS-D	Base	3	2.8	1.52	400	2.65	400	1.7	BMS
BMS-E	Base	2	1.5	1.17	200	2.5	800	2.5	BMS
BMS-F	Acid	3	0.59	0.7	20	0.7	20	0.69	BMS
BMS-G	Acid	2	3.73	1.1	150	5.2	600	1.2	BMS
BMS-H	Base	3	−3.37	0.7	500	0.75	850	0.75	BMS
BMS-I	Base	3	2.3	0.94	25	0.86	25	0.61	BMS
BMS-J	Base	2	5.3	1.38	15	1.5	15	1.2	BMS
BMS-K	Base	2	2.08	1.25	–	–	300	1.09	BMS
BMS-L	NI	4	3.26	1.08	–	–	400	0.91	BMS
BMS-M	NI	2	4.6	2.26	75	2.3	75	1.87	BMS
BMS-N	Base	2	3.1	0.91	50	1.16	300	2.3	BMS
BMS-O	Base	2	4.9	2.3	50	2.3	40	1.2	BMS
BMS-P	Base	2	2.3	4.23	150	5.5	800	3.7	BMS
BMS-Q	Acid	2	1	–	300	0.83	300	1.08	BMS
Ketoconazole	Base	2	3.54	2.46	–	–	600	1.45	(39)
Ribavirin	Base	3	−2.6	1.2	–	–	200	1.42	(40)
Triclabendazole	Base	2	6.34	10.01	–	–	600	3.7	(26)
Danazol	NI	2	4.7	3.56	–	–	100	3	(41)
Celecoxib	Acid	2	3	–	100	2.2	200	1.2	(42)

No value denotes the drug was not tested in that model. Molecule type: acid, base, or non-ionizable (NI)